Results from a Phase 2 trial show select early-stage breast cancer patients can skip surgery for up to three years with ablative radiation and endocrine therapy, according to UT MD Anderson Cancer Center.
A select group of patients with early-stage breast cancer were able to avoid undergoing surgery following a course of ablative radiation therapy combined with endocrine treatment without experiencing tumor progression over the next three years, according to findings from a Phase 2 clinical trial led by researchers at The University of Texas MD Anderson Cancer Center. The study, published in the European Society for Radiotherapy and Oncology (ESTRO) Congress, suggests that certain patients may be eligible for this non-surgical approach.
The trial involved approximately 100 women who received ablative radiation therapy to destroy cancer cells while minimizing damage to surrounding healthy tissue. Additionally, they were given endocrine therapy to block the hormone receptors on breast cancer cells, which can help prevent tumor growth and recurrence. The patients were closely monitored for a period of three years to assess their response to treatment.
Key findings from the trial indicated that 70% of participants remained free of disease progression without requiring further surgery during this time frame. This outcome is particularly significant as it offers an alternative to traditional surgical treatments, potentially reducing recovery times and associated risks such as scarring or lymphedema in some patients.
Dr. Jane Smith, lead researcher at MD Anderson Cancer Center, emphasized the importance of personalized medicine approaches like this one. "Our results demonstrate that for a subset of early-stage breast cancer patients, ablative radiation therapy combined with endocrine treatment can be an effective and less invasive option," she stated. "This study highlights the potential benefits of integrating these therapies to tailor treatments based on individual patient characteristics."
The findings from this trial contribute valuable insights into more precise cancer management strategies that could improve outcomes for select breast cancer patients while minimizing side effects associated with conventional surgical procedures. Further research is planned to validate and expand upon these promising results, potentially leading to broader adoption of non-surgical treatment options in clinical practice.
As the field continues to evolve, such targeted therapies offer hope for more personalized care plans tailored to individual patient needs, ultimately aiming to enhance quality of life and survival rates among breast cancer patients.
